Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 695

Results For "ED"

9532 News Found

Lupin gets EIR from USFDA for its Ankleshwar facility
Drug Approval | October 03, 2022

Lupin gets EIR from USFDA for its Ankleshwar facility

The inspection of the facility was conducted from August 16-19, 2022.


SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru
Healthcare | October 03, 2022

SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru

This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant


Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences
News | October 03, 2022

Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences

The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.


Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
Drug Approval | October 01, 2022

Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension

Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).


Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series
News | October 01, 2022

Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series

Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic


Philips shareholders appoint Roy Jakobs as next President and CEO
People | October 01, 2022

Philips shareholders appoint Roy Jakobs as next President and CEO

Roy is the right successor to lead Philips’ efforts to help improve the health and well-being of people globally


Lupin launches Sildenafil for Oral Suspension in US
Drug Approval | September 30, 2022

Lupin launches Sildenafil for Oral Suspension in US

Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US


Lupin receives warning letter from US FDA
Drug Approval | September 30, 2022

Lupin receives warning letter from US FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility